Login / Signup

Nanomedicine-based commercial formulations: current developments and future prospects.

Raj Kumar ThapaJong Oh Kim
Published in: Journal of pharmaceutical investigation (2022)
To date, the Food and Drug Administration and the European Medicines Agency have approved several nanomedicines, which are now commercially available. However, several critical challenges, including reproducibility, proper characterization, and biological evaluation, e.g., via assays, are still associated with their use. Therefore, rigorous studies alongside stringent guidelines for effective and safe nanomedicine development and use are still warranted. In this study, we provide an overview of currently available nanomedicine-based formulations. Thus, the findings here reported may serve as a basis for further studies regarding the use of these formulations for therapeutic purposes in near future.
Keyphrases
  • drug administration
  • current status
  • cancer therapy
  • case control
  • high throughput
  • drug delivery
  • risk assessment
  • climate change